Lorsaid OD Tablet ER contains Lornoxicam 16mg, a potent non-steroidal anti-inflammatory drug (NSAID) belonging to the oxicam class, indicated for the management of acute and chronic pain associated with inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Lornoxicam exerts its therapeutic effect by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins responsible for inflammation, pain, and fever. The extended-release (ER) formulation of Lorsaid OD allows for once-daily dosing, providing sustained plasma concentrations and prolonged analgesic and anti-inflammatory effects, which enhances patient compliance. It is particularly useful in conditions requiring consistent pain control without frequent dosing. Lorsaid OD Tablet ER should be administered with caution in patients with a history of gastrointestinal ulcers, bleeding disorders, cardiovascular diseases, or renal impairment. Common adverse effects may include gastrointestinal discomfort, nausea, dizziness, and headache. It is contraindicated in patients with hypersensitivity to lornoxicam or other NSAIDs, and during the third trimester of pregnancy due to the risk of fetal harm. Monitoring of renal and hepatic function is recommended during prolonged therapy. Lorsaid OD Tablet ER should be used at the lowest effective dose for the shortest duration necessary to minimize potential risks.